Skip to main content
S&P 5007,568.92+0.36%DOW51,786.72-0.38%NASDAQ25,372.01+0.83%BTC$76,850.00-0.36%ETH$2,261.28+0.13%GOLD$3,968.20+0.71%OIL$95.60-0.51%
Smart Investors Daily
SID Premium
MB

NASDAQ · MBRX

Moleculin Biotech, Inc.

Healthcare · Biotechnology

$8.30

Down-$0.02 (-0.24%)

Updated Nov 4, 2026, 3:17 AM

SID Score

5.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
6.01M
P/E ratio
-0.18
Dividend yield
0.00%
52-week range
$0.16 – $15.75
Volume
12.49K
Avg. volume
194.99K

Price performance · MBRX

MBRX price history

1M range · 0 trading sessions · Daily adjusted prices

MBRX does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest MBRX news

The latest Smart Investors Daily articles mentioning MBRX.

Stock researchCompany · Overview

MBRX research

Overview

Company profile and research snapshot.

Company profile

Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$170.00
Implied upside
—
Analysts
9
MBRX recent ratings
DateFirmRatingTarget
Aug 28, 2026HC Wainwright & Co.Buy—
Mar 24, 2026HC Wainwright & Co.Buy—
Dec 11, 2025HC Wainwright & Co.Buy—
Sep 10, 2025HC Wainwright & Co.Buy—
Aug 27, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 30, 2026

Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027

Milestone underscores execution of pivotal Phase 2/3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (AML) Fully treated, randomized, double-blind n=90 Part A population sets up Annamycin dose selection for Part B, with balanced representation of AML patients who failed 7+3 chemotherapy and venetoclax-based regimens HOUSTON, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today ann

Yahoo · Oct 20, 2026

Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial

Access the Moleculin CEO Corner here HOUSTON, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that it has released the next segment on its CEO Corner, a platform featuring Walter Klemp, Chief Executive Officer. In this episode of CEO Corner, Moleculin Biotech Chairman and CEO Walter Klemp discusses the progress of the Company’s Phase 2/3 MIRACLE trial evaluating Annamycin in combination with high-dose cytarabine (HiDAC) for

Yahoo · Oct 16, 2026

Moleculin Announces Reverse Stock Split

HOUSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on October 20, 2026, and the Company’s common stock will open for trading on The Nasdaq Capital Market

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By